← Back to patent-cliff list
Suramin sodium (Kuzani Pharmaceuticals)
Tier C — Watch / tradeSuramin sodium (Kuzani Pharmaceuticals)
Kuzani Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Heparanase
Indications (approved)：自闭症谱系障碍
Regional status
US
Phase II
2025-04-09
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Suramin sodium (Kuzani Pharmaceuticals)?
Approved indications include: 自闭症谱系障碍.
When does the Suramin sodium (Kuzani Pharmaceuticals) patent expire?
No public expiry year is available for Suramin sodium (Kuzani Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Suramin sodium (Kuzani Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30